Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) has been reported to be the third most common malignant tumor and has the highest rate of mortality. To increase the chemotherapy efficacy of HCC, a drug delivery system featured with desirable active targeting ability, delivery efficiency and immune evasion is in high demand. We have developed a drug nanocarrier by utilizing a homotypic cancer cell membrane for targeted chemotherapy of HCC. Structurally, the homotypic HepG2 cell membrane was used as the cloak, and a poly (lactic- -glycolic acid) (PLGA) nanoparticle as the core, resulting in the nanocarrier . The nanoparticles exhibit excellent targeting ability toward HepG2 cells. Doxorubicin (Dox) carried by possesses high delivery efficiency and a remarkable therapeutic effect. In experiments, delivers Dox directly to the tumor lesion of nude mice, and tumor volume decreases by approximately 90% after treatment. We have developed a drug nanocarrier by utilizing a homotypic cancer cell membrane for targeted chemotherapy of HCC with excellent active targeting ability. This biomimetic platform not only effectively treats HCC but also provides a sound strategy for the treatment of other cancers changes in the corresponding homotypic cancer cell membrane.